Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | CCKAR | P32238 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459742 | 0.84 | TNF (0.52) | GAAHTTLMNAFFAR1ALOX5 | |
| SCHEMBL7891728 | 0.82 | L3MBTL1 (0.68) | GAAHTTFFAR1AKR1C3AKR1C2 | |
| SCHEMBL3913073 | 0.81 | GAA (0.53) | GAAHTTLMNAAKR1C2AKR1C1 | |
| SCHEMBL27702953 | 0.80 | TNF (0.55) | GAAHTTLMNAFFAR1ALOX5 | |
| SCHEMBL3910097 | 0.80 | GAA (0.51) | GAAHTTLMNAL3MBTL1POLB | |
| SCHEMBL8585877 | 0.80 | L3MBTL1 (0.51) | GAAHTTLMNAFFAR1AKR1C3 | |
| SCHEMBL31344401 | 0.79 | AKR1C3 (0.54) | GAAHTTAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL21194023 | 0.79 | AKR1C3 (0.54) | GAAHTTAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7868149 | 0.79 | FFAR1 (0.49) | FFAR1ALOX5AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL490727 | 0.77 | AKR1C3 (0.55) | FFAR1AKR1C3AKR1C2AKR1C1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476759-B2 | e.g. 4-Amino-3-(4'-cyano-1,1'-biphenyl-4-yl)-4-oxobutanoic acid; antiinflammatory , anticarcinogenic, antiasthmatic agent; autoimmune disorder; osteoarthritis, rubella, Alzheimer's, Parkinson's diseases, epilepsy, osteoporosis | GLAXO GROUP LIMITED (GB) | 2009-01-13 | — | — | US | disclosed |
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1654218-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016868-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP9, MMP24 | GAA 1135/4885HTT 4566/4885LMNA 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.